SCYNEXIS, Inc. filed a Form S-3 registration statement on November 5, 2026, to replace its expiring shelf registration and carry forward up to $200,000,000 in previously registered but unsold securities.

Key Highlights

  • Replacement filing: The new registration statement replaces File No. 333-275520, originally filed November 13, 2023, which is due to expire on November 27, 2026.
  • Full amount unsold: As of the filing date, all $200,000,000 of securities previously registered under the expiring statement remain unsold, according to the filing.
  • No new securities added: The company disclosed that no additional securities are being registered under this registration statement.
  • No additional fee: Registration fees previously paid are being carried forward; no additional registration fee is due.
  • Public float: As of November 3, 2026, the aggregate market value of common stock held by non-affiliates was approximately $52.5 million, based on the closing price on October 1, 2026.
  • Recent share price: The last reported sale price of common stock on November 4, 2026, was $3.84 per share.
  • Offering cap constraint: Pursuant to General Instruction I.B.6 of Form S-3, the company disclosed it may not sell securities in a public primary offering exceeding one-third of its public float in any 12-month period unless the public float rises to $75.0 million or more.

SCYNEXIS Carries Forward $200M Shelf Capacity as 2023 Registration Nears Expiration

SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company headquartered at 1 Evertrust Plaza, 13th Floor, Jersey City, NJ, filed this Form S-3 registration statement on November 5, 2026, under Rule 415(a)(6) of the Securities Act of 1933. According to the filing, the purpose is to replace the company's prior shelf registration (File No. 333-275520), which was filed on November 13, 2023, and is set to expire on November 27, 2026.

The filing states that all $200,000,000 in maximum aggregate offering price of securities previously registered under the expiring statement remain unsold and are being carried forward in their entirety. The company disclosed that no additional securities are being registered and that no new registration fee is required, as the fees paid in connection with the prior registration are being applied to this new statement. The securities covered include common stock, preferred stock, debt securities, and warrants, which may be offered individually or in combination on a delayed or continuous basis.

The company noted that its public float, as of November 3, 2026, was approximately $52.5 million, calculated in accordance with General Instruction I.B.6 of Form S-3. The filing further disclosed that the company has not sold any securities under that instruction during the 12 calendar months prior to and including the prospectus date. The filing also states that until the new registration statement becomes effective, the company may continue to issue and sell securities under the expiring registration for up to 180 days after November 27, 2026, pursuant to Rule 415(a)(5)(ii). Upon effectiveness of the new registration statement, the offering under the expiring registration will be deemed terminated.

What Was Disclosed

SCYNEXIS filed a Form S-3 on November 5, 2026, to replace an expiring shelf registration by carrying forward all $200,000,000 in unsold securities, with no new securities added and no additional registration fee assessed.